CPSH
CPS Technologies Corporation
CPSH trails on the overall score without a compensating advantage in the available component scores.
NVDA
NVIDIA Corporation
NVDA has the edge over CPSH overall, supported by stronger valuation and stronger fundamentals.
CPSH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Weak | |
| Strong |
CPSH's balance sheet is currently strong, and its revenue and profitability are stable, but its cash flow is weak.
NVDA Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Strong | |
| Strong | |
| Strong |
NVDA's revenue, profitability, cash flow and balance sheet are all currently strong.
CPSH PE Valuation
CPSH has no meaningful PE right now: it lost money over the past year.
NVDA PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $166 | — |
| Current | 21x | $166 | — |
| Cheap | 44x | $345 | +108% |
| Fair | 65x | $511 | +207% |
| Expensive | 93x | $734 | +342% |
Historical ranges are pointers, not guarantees.
NVDA's PE is in its cheap range at 21x. If earnings grow as analysts expect, today's price would be 12x next year's earnings.
CPSH Forward outlook
There aren't enough analyst estimates for CPSH to show an outlook.
NVDA Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Weakening | |
| Broad | |
| Moderate |
Analysts expect strong earnings and revenue growth for NVDA, but weaker profitability.
CPSH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $0.00 | +$0.04 |
| Q2 2026 | -$0.01 | +$0.11 |
| Q1 2026 | $0.00 | +$0.20 |
| Q4 2025 | $0.03 | +$0.25 |
| Q3 2025 | -$0.04 | +$0.10 |
| Q2 2025 | -$0.12 | -$0.06 |
| Q1 2025 | -$0.20 | -500% |
| Q4 2024 | -$0.22 | -344% |
CPSH is still losing money, but far less than before: $0.00 per share over the past year, against $0.22 at its worst in late 2024.
NVDA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $13.77 | +74% |
| Q3 2026 | $7.91 | +125% |
| Q2 2026 | $6.53 | +111% |
| Q1 2026 | $4.90 | +67% |
| Q4 2025 | $4.03 | +59% |
| Q3 2025 | $3.51 | +65% |
| Q2 2025 | $3.10 | +81% |
| Q1 2025 | $2.94 | +147% |
| Q4 2024 | $2.54 | +234% |
NVDA has the edge over CPSH on earnings, with more consistent year-over-year improvement.
CPSH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $8.9M | +1.1% |
| Q2 2026 | $8.3M | +2.9% |
| Q1 2026 | $7M | -6.4% |
| Q4 2025 | $8.2M | +38% |
| Q3 2025 | $8.8M | +107% |
| Q2 2025 | $8.1M | +61% |
| Q1 2025 | $7.5M | +27% |
| Q4 2024 | $5.9M | -12% |
CPSH's revenue is growing: $9M last quarter, up 1.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 4% | +0.9 points |
| Q2 2026 | -3.1% | -4.8 points |
| Q1 2026 | -7.4% | -9.2 points |
| Q4 2025 | -1.2% | +21 points |
| Q3 2025 | 3.1% | +38 points |
| Q2 2025 | 1.7% | +28 points |
| Q1 2025 | 1.7% | +6.1 points |
| Q4 2024 | -22% | -24 points |
CPSH's operating margin was 4% last quarter, up 0.9 points from the same quarter a year ago.
NVDA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $96.2B | +106% |
| Q2 2026 | $81.6B | +85% |
| Q1 2026 | $68.1B | +73% |
| Q4 2025 | $57B | +62% |
| Q3 2025 | $46.7B | +56% |
| Q2 2025 | $44.1B | +69% |
| Q1 2025 | $39.3B | +78% |
| Q4 2024 | $35.1B | +94% |
NVDA has the edge over CPSH on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 66% | +5.4 points |
| Q2 2026 | 66% | +17 points |
| Q1 2026 | 65% | +3.9 points |
| Q4 2025 | 63% | +0.8 points |
| Q3 2025 | 61% | -1.2 points |
| Q2 2025 | 49% | -16 points |
| Q1 2025 | 61% | -0.5 points |
| Q4 2024 | 62% | +4.9 points |
NVDA has the edge over CPSH on profitability, with a higher operating margin.
CPSH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$310.2K | -135% |
| Q2 2026 | -$2.4M | -601% |
| Q1 2026 | -$767.8K | +$578K |
| Q4 2025 | -$494.4K | +$974.6K |
| Q3 2025 | $876.8K | +$2.1M |
| Q2 2025 | $476.4K | +$2.1M |
| Q1 2025 | -$1.3M | -$1.2M |
| Q4 2024 | -$1.5M | -3294% |
CPSH has burned cash in six of the last eight quarters: −$4M over the past year, against −$1M the year before.
NVDA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $21.4B | +59% |
| Q2 2026 | $48.6B | +86% |
| Q1 2026 | $34.9B | +124% |
| Q4 2025 | $22.1B | +32% |
| Q3 2025 | $13.5B | -0.3% |
| Q2 2025 | $26.2B | +75% |
| Q1 2025 | $15.6B | +38% |
| Q3 2024 | $13.5B | +113% |
NVDA has the edge over CPSH on cash generation, producing positive trailing cash flow while its opponent burns cash.
CPSH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +4.8% | +903K shares |
| 1 year | +35% | +5.1M shares |
| 3 years | +35% | +5.1M shares |
| 5 years | +33% | +4.9M shares |
| Available history | +50% | +6.6M shares |
CPSH has 20M diluted shares, up 35% from a year ago.
NVDA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -106M shares |
| 1 year | -1% | -247M shares |
| 3 years | -2.8% | -705M shares |
| 5 years | -4.1% | -1B shares |
| Available history | -1.8% | -435M shares |
NVDA has the edge over CPSH on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $19.7B |
| Q2 2026 | $19.3B |
| Q1 2026 | $3.8B |
| Q4 2025 | $12.5B |
| Q3 2025 | $9.7B |
| Q2 2025 | $14.1B |
| Q1 2025 | $7.8B |
| Q4 2024 | $11B |
NVDA spent $55.3B buying back its own shares over the past year, up 30% from the year before.
CPSH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -36.2x | Net Cash |
| Q1 2026 | -15.1x | Net Cash |
| Q4 2025 | -4.3x | Net Cash |
| Q1 2024 | -7.1x | Net Cash |
| Q4 2023 | -4.0x | Net Cash |
| Q3 2023 | -3.7x | Net Cash |
| Q2 2023 | -2.9x | Net Cash |
| Q1 2023 | -2.6x | Net Cash |
CPSH has the edge over NVDA on leverage, with a lower net debt burden relative to earnings.
NVDA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.1x | Very low |
| Q2 2026 | -0.0x | Net Cash |
| Q1 2026 | -0.0x | Net Cash |
| Q4 2025 | -0.0x | Net Cash |
| Q3 2025 | -0.0x | Net Cash |
| Q2 2025 | -0.1x | Net Cash |
| Q1 2025 | -0.0x | Very low |
| Q4 2024 | -0.0x | Net Cash |
NVDA's net debt is less than a year of its operating earnings (EBITDA), after holding more cash than debt a year ago.
CPSH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 48.8 | Neutral |
| Stochastic | 36.9 | Neutral |
CPSH's weekly RSI is 49 (neutral) and its Stochastic is 37 (neutral).
NVDA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 33.4 | Neutral |
| Stochastic | 18.1 | Oversold |
NVDA's weekly RSI is 33 (neutral) and its Stochastic is 18 (oversold).
CPSH PE vs Technology Sector
| Metric | CPSH | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 28x | — |
CPSH has no meaningful PE right now: it lost money over the past year.
NVDA PE vs Technology Sector
| Metric | NVDA | Sector median | Relative |
|---|---|---|---|
| PE | 21x | 28x | 25% below |
| PE % | 0 | 35 | 35 pts below |
NVDA is trading at 21x earnings, a 25% discount to the Technology sector's median of 28x.
CPSH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.72 | 10% above |
| 20 week MA | $4.04 | 1.5% above |
| 50 week MA | $4.51 | 9.1% below |
| 100 week MA | $3.52 | 16% above |
| 200 week MA | $2.89 | 42% above |
CPSH has the edge over NVDA on trend strength, trading above more of its moving averages.
NVDA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $208.9 | 20% below |
| 20 week MA | $212.0 | 22% below |
| 50 week MA | $199.9 | 17% below |
| 100 week MA | $175.1 | 5.1% below |
| 200 week MA | $123.6 | 34% above |
NVDA has fallen below most of its moving averages, though it's still 34% above its 200-week average.
CPSH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $1.05 | $2.29 | +118% |
| 2021 | $2.29 | $4.34 | +90% |
| 2022 | $4.34 | $2.75 | -37% |
| 2023 | $2.75 | $2.35 | -15% |
| 2024 | $2.35 | $1.62 | -31% |
| 2025 | $1.62 | $3.21 | +98% |
| 2026 YTD | $3.21 | $4.10 | +28% |
CPSH has the edge over NVDA on returns for 2026, with the stronger performance.
NVDA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $5.92 | $13.0 | +119% |
| 2021 | $13.0 | $29.6 | +128% |
| 2022 | $29.6 | $15.2 | -49% |
| 2023 | $15.2 | $49.5 | +226% |
| 2024 | $49.5 | $137.0 | +177% |
| 2025 | $137.0 | $190.5 | +39% |
| 2026 YTD | $190.5 | $166.2 | -13% |
NVDA's yearly returns have swung widely, from +226% in 2023 to −49% in 2022. It's down 13% so far in 2026.